{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-004414","form_type":"8-K","ticker":"TNYA","cik":"0001858848","company_name":"Tenaya Therapeutics, Inc.","filed_at":"2022-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.904972+00:00","generated_at":"2026-06-26T20:09:54.790853+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tenaya reports FY2021 net loss $72.7M; cash runway into H2 2023; three programs advancing","bullets":["Cash, equivalents and investments $251.3M at Dec 31, 2021 vs $128.5M year-end 2020; runway to H2 2023.","R&D expenses $54.4M in FY2021 (up from $31.1M); G&A $18.4M (up from $7.8M).","Net loss $72.7M ($4.10/share) vs $38.4M ($39.50/share) in 2020.","TN-201 IND submission for MYBPC3 HCM expected H2 2022; TN-301 IND H2 2022; TN-401 IND in 2023.","Appointed Sunita Sethi (SVP Regulatory) and Naymisha Patel (SVP Quality); cGMP facility in Union City to be operational H1 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-004414","json":"https://secwatch.observer/filing/0000950170-22-004414.json","markdown":"https://secwatch.observer/filing/0000950170-22-004414.md","text":"https://secwatch.observer/filing/0000950170-22-004414.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858848/000095017022004414/0000950170-22-004414-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858848/000095017022004414/tnya-20220323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T20:09:54.790853+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}